October 20, 2014

Big Blue Test

Today, when I ride my bike, I'll do the Big Blue Test. What activity will you do when you do the Big Blue Test

Here is what I'll do:

1. Test My Blood Glucose.  (If you do not have diabetes, you can skip the testing steps.)
2. Get Active. I will ride my bike!
3. I'll Test Again.  After riding. In the past, on average, Big Blue Testers have seen their blood glucose level drop 20% after 14-20 minutes of exercise.
4. I'll Share My Results.  Answer the questions in the right column of this page. And don’t forget to talk about your experience on social media.

Download the App

    Big Blue Test diabetes exercise app available in itunesBig Blue Test App available in Google Play 


StripSafely is at it again! #Vote4DM is a targeted awareness campaign that lets you tell Congress you know that there are three bills related to diabetes on the Hill and they need act on them. Go to StripSafley.com and  click Vote4DM above or TWITTER below. 


Our Ask

  • Join  Tweet-ins 8:00 PM-ish eastern on October 22 and 29.
  • Go here http://www.stripsafely.com/the-twitter-page/
  • Find your elected officials.
  • Click the 3 links. Coordinate, Educate and CGM for your Senators and Representative. (Bonus points for Tweeting Congressional leadership too.)

We figured out who is in the diabetes caucus, who has already cosponsored what, and the bill numbers and adjust the Tweets to fit.

All you do is Point and Click, what could be easier?

The Point

"It is impossible to move someone to action without first getting his or her attention," Back to Basics. So lets use simple tools to get attention, when Congress is listening, aka a few days before the election. Will it change a lot of their minds? No.

This it help a process of getting attention, start the wheel squeaking and our community asking. 

DEXCOM Share Approved

From the News Wire:

FDA Approves Dexcom SHARE™, the First Remote Mobile Communications Device Used for Continuous Glucose Monitoring (CGM)
Now critical glucose data from the Dexcom G4® PLATINUM Continuous Glucose Monitoring System can be remotely monitored using a mobile device 
SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its CGM remote mobile communications device: Dexcom SHARE. Dexcom SHARE, an accessory to the Dexcom G4® PLATINUM Continuous Glucose Monitoring System, uses a secure wireless connection to transmit the glucose levels of a person with diabetes to the smartphones of up to five designated recipients, or “followers.” These followers can remotely monitor a patient’s glucose information and receive alert notifications from almost anywhere via their Apple® iPhone® or iPod® touch. With Dexcom SHARE, parents and personal caregivers can monitor a child’s or loved one’s glucose data from a remote location, giving them peace of mind and reassurance when they are apart.  
“Dexcom SHARE represents a significant advance in diabetes care by allowing people with diabetes to share important glucose information with their loved ones from afar,” said Terrance H. Gregg, Chief Executive Office of Dexcom. “With Dexcom SHARE, users, parents and personal caregivers now have a new tool to dramatically improve how they communicate about their diabetes.”

Disclosure: I have Dexcom Share but that has little to do with pleasure at seeing this. 

October 15, 2014

Hey Adam needs a hand, Little help?

This is from my good friend and inspiration to bicycle, Adam Brown at diaTribe. Help him out OK? Just to be clear, diaTribe is asking to help better focus on what matters to PWD when we do the next round of #DOCasksFDA, not FDA asking. Go us!
Hello DOC friends! 

On November 3, the FDA will host an unprecedented discussion between the diabetes community and senior agency leadership (both drugs and devices). The event will be live webcast from 1 - 4 pm. We want this to be nothing short of a home run. The event will include a panel of patients (T1 and T2), as well as representatives from ADA, JDRF, and diaTribe. As a community, our job is to present the numerous challenges we as patients face each day, and we need as many opinions as possible to be a part of this discussion! With FDA, ADA, JDRF, and dQ&A input, we have created a survey posted at www.diaTribe.org/surveyWe are asking the entire diabetes community (T1 and T2!) to please fill out this short survey and share thoughts on what's important when it comes to living with diabetes. This feedback will go DIRECTLY to FDA and help influence the conversation on November 3

FDA is currently working on the registration to sign up for this webcast event; as we understand it, this should be posted within the week. We will be in touch with that information and a finalized agenda as soon as we have it. For now, it is mission critical to have a massive response to the survey. We need to show the FDA that patients care about these issues, that patients have valuable input to share, and that the treatment options we have are still not good enough.

Thank you on behalf of our entire team for your help in spreading the word on the survey and about the event. We’re truly excited about the potential to open the lines of communication with the FDA, which for too long has been a black box. We need more patient input into the drug and device approval process, and we see November 3 as a very key avenue to making that happen. Let’s show the FDA how committed our community is.

very best wishes,

October 7, 2014

Glooko Launches ‘MeterSync Blue’

From: http://www.prweb.com/releases/2014/10/prweb12217624.htm

Glooko Launches ‘MeterSync Blue’ to Bluetooth-Enable Tens of Millions of Blood Glucose Meters Worldwide
With the addition of 'MeterSync Blue,' Glooko's diabetes management platform enables remote patient monitoring by syncing blood glucose readings from more than 30 meters to supported Apple and Android devices. 
Glooko Inc., announced today the launch of Glooko MeterSync Blue, strengthening its position as the industry leader in delivering a mobile, software as a service (SaaS) diabetes remote monitoring and population management platform. Now patients can utilize Bluetooth to connect any of more than 30 popular blood glucose meters to the Glooko platform on Android or Apple devices, as an easier alternative to a physical connection with the current Glooko MeterSync cable.
With the addition of the Glooko MeterSync Blue – featuring Bluetooth Smart™ and Glooko’s FDA-cleared technology - the company’s diabetes management platform provides health systems and payer groups the ability to more cost-effectively enroll diabetes patients into remote monitoring programs without the need for patients to switch to costly, wireless-enabled, blood glucose meters developed specifically for telemedicine. Instead, health systems and payer groups can leverage the tens of millions of meters already deployed to patients worldwide.

October 6, 2014

Pediatric Vibe Approve in the Great White Northland

From the press release: 

Animas® Vibe® Insulin Pump and Continuous Glucose Monitoring System Now Approved for Children with Type 1 Diabetes in Canada

BURNABY, British ColumbiaOct. 6, 2014 /CNW/ -- Animas Canada, a division of LifeScan Canada Ltd., today announced the launch of the Animas® Vibe® insulin pump and Dexcom G4® PLATINUM continuous glucose monitoring (CGM) system, for the pediatric market1 in Canada.
"Earlier this year, we introduced Animas® Vibe® to adult Canadians living with diabetes, so we are pleased to expand this offering to the pediatric population," said Paul Flynn, North American Sales Director, Animas Corporation. "Now children and their parents can manage their diabetes with a system that combines a world class insulin pump with state-of-the-art CGM technology."
More: http://www.newswire.ca/en/story/1423474/animas-vibe-insulin-pump-and-continuous-glucose-monitoring-system-now-approved-for-children-with-type-1-diabetes-in-canada

September 19, 2014

The Bionic P With Katie C

In case you missed it, Katie Couric has a great story on Ed Damiano.



September 16, 2014

OmniPool? TidePod?

Congratulations to both, either and the combination. From the post on Tidepool's site:

Insulet and Tidepool

Raul Oliva, Marketing Director at Insulet

Insulet is pleased to announce we are opening our data protocol to Tidepool to enable OmniPod users to upload their insulin pump and integrated blood glucose meter data to the Tidepool platform and future Tidepool applications. With the announcement from Dexcom regarding their agreement with Tidepool in August, users of both OmniPod insulin pumps and Dexcom continuous glucose monitors will see their data from both devices in one place in future Tidepool applications. (more)


September 3, 2014

From the News Wire: CE Mark for Abbott's New Glucose Monitoring System

From The Abbott Press Release


ABBOTT PARK, Ill., Sept. 3, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has received CE Mark (Conformite Europeenne) for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for people with diabetes. The system eliminates the need for routine finger pricks1, reading glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days. In addition, no finger prick calibration is needed—a key differentiator from current continuous glucose monitoring systems. The system will be available in seven countries across Europein the coming weeks. 
Abbott′s FreeStyle Libre System consists of a small, round sensor—approximately the size of a two Euro coin—worn on the back of the upper arm, which measures glucose every minute in interstitial fluid through a small (5mm long, 0.4mm wide) filament that is inserted just under the skin and held in place with a small adhesive pad. A reader is scanned over the sensor to get a glucose result painlessly in less than one second. Scanning can take place while the sensor is under clothing2, making testing more discreet and convenient. Each scan displays a real-time glucose result, a historical trend and the direction the glucose is heading. The reader holds up to 90 days of data, providing a historical snapshot of glucose levels over time. The FreeStyle Libre System software enables the data to be presented in a user-friendly, visual chart for both healthcare professionals and patients, driving a more productive discussion around treatment and any necessary modification. 
"The FreeStyle Libre System fulfills a major need for people living with diabetes," said Robert Ford, senior vice president, Diabetes Care, Abbott. "Our customers told us that the pain, inconvenience and indiscretion of finger pricking were the key reasons they weren't managing their diabetes as well as they should. Addressing these concerns has guided the development of FreeStyle Libre – a transformational product designed to not only remove the pain of finger pricking but also seamlessly integrate into their daily lives."  
The FreeStyle Libre System will be available in France, Germany, Italy, Netherlands, Spain, Sweden and United Kingdom in the coming weeks and will be available for purchase online through a website in each market. 
More including footnotes:


August 28, 2014

Unexpected Ways the DOC Improves Diabetes

I am a fan of community. The diabetes community in particular and the value it bring by connecting peers and empowering self care. Those connections do even more. 

Our friends at Glu just posted an article about an infusion set study. These days in and evidence based health environment studies matter. What's that got to do with community? Well by reaching out to the community Glue filled over 80% of the study, in just two days. Glu helped the community help itself    with faster studies. Heres is what the studies Alysa Sampson Perrin said:
“We were very fortunate to be able to conduct this study using Glu, it allowed for rapid recruitment with over 200 of the 243 total participants enrolling within 2 days of announcing the study."

One month ago advocates let by Anna McCollister-Slipp had a conversation with FDA on Medical Device Data Systems. In that FDA asked for patents views on the risk and benefits of data, specifically real time data from CGM moving to a device data system to other displays. YDMV wrote the it here.  In one month, with enthusiastic support from the CGM in the Cloud Facebook group the community put over 500 comments into FDA's open docket. I think that is a record response from the diabetes community to a FDA request for comments.

Our community is strong, we support each other, we empower research, we work with regulators and we can do more. My friend Michael outlines that vision:

Be a part. Take the MasterLab survey.